Ulcerative Colitis Research Reagents

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by continuous mucosal inflammation extending proximally from the rectum, affecting approximately 5 million people worldwide. Dysregulated Th2/Th17 immune responses and epithelial barrier dysfunction drive pathogenesis, with mucosal healing now recognized as the primary therapeutic endpoint. Current treatment strategies include 5-aminosalicylates (5-ASA), biologics — anti-TNF-α (infliximab, adalimumab), anti-α4β7 integrin (vedolizumab), anti-IL-12/23 (ustekinumab), and anti-IL-23 p19 (mirikizumab) — JAK inhibitors (tofacitinib, upadacitinib), and S1P receptor modulators (ozanimod, etrasimod). Preclinical and translational research relies on validated antibodies and recombinant proteins targeting these pathways for mechanism-of-action studies, biomarker assay development, and biosimilar characterization.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Ulcerative Colitis Research Reagents — key pathogenic pathways including mucosal inflammation, Th2/Th17 immune dysregulation, epithelial barrier dysfunction, TNF-α signaling, α4β7 integrin gut-homing, IL-23/Th17 axis, and JAK-STAT cascade

Fig. 1 Key pathogenic pathways and research targets in ulcerative colitis. TNF-α drives mucosal inflammation and epithelial apoptosis; α4β7 integrin mediates gut-selective lymphocyte homing via MAdCAM-1; IL-23 activates pathogenic Th17 cells; JAK-STAT signaling amplifies pro-inflammatory cytokine cascades; calprotectin (S100A8/A9) serves as a non-invasive biomarker. Key research targets highlighted in orange.

abinScience provides validated recombinant proteins, monoclonal antibodies, biosimilar reference antibodies, and ELISA kits for UC research — including anti-TNF-α biosimilars (infliximab, adalimumab), anti-α4β7 integrin (vedolizumab) reference antibody, anti-IL-23 p19 (mirikizumab) reference antibody, calprotectin (S100A8/S100A9) ELISA kits, and JAK pathway proteins for inhibitor screening. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

TNF-α — TNF-α is a central pro-inflammatory cytokine driving mucosal inflammation, epithelial apoptosis, and tissue destruction in UC. Anti-TNF-α therapies (infliximab, adalimumab, golimumab) remain first-line biologics. abinScience offers biosimilar reference antibodies (infliximab, adalimumab), recombinant TNF-α proteins, and anti-TNF-α monoclonal antibodies for bioassay development, anti-drug antibody (ADA) monitoring, and biosimilar comparability studies.
→ Browse TNF-α antibodies & proteins

α4β7 Integrin / Vedolizumab — α4β7 integrin mediates gut-selective lymphocyte homing through interaction with MAdCAM-1 on intestinal endothelium. Vedolizumab, a gut-selective anti-α4β7 antibody, blocks this trafficking pathway. abinScience offers the vedolizumab reference antibody and recombinant integrin α4/β7 proteins for receptor occupancy assays, mechanism-of-action studies, and competitive binding research.
→ Browse α4β7 Integrin antibodies & proteins

IL-23 p19 / Mirikizumab — IL-23, through its p19 subunit, drives pathogenic Th17 cell expansion and sustained mucosal inflammation in UC. Selective anti-IL-23 p19 antibodies (mirikizumab, guselkumab, risankizumab) represent the latest biologic class in IBD. abinScience offers the mirikizumab reference antibody, recombinant IL-23 (p19/p40) proteins, and anti-IL-23 p19 monoclonal antibodies for bioassay development and pathway research.
→ Browse IL-23 p19 antibodies & proteins

Calprotectin (S100A8/S100A9) — Fecal calprotectin, a heterodimer of S100A8 and S100A9, is the most widely used non-invasive biomarker for UC disease activity monitoring and mucosal healing assessment. abinScience offers anti-calprotectin monoclonal antibody pairs, recombinant S100A8/S100A9 proteins, and calprotectin ELISA kits for quantitative measurement, assay development, and clinical correlation research.
→ Browse Calprotectin antibodies & ELISA kits

JAK1 / JAK3 — JAK-STAT signaling amplifies pro-inflammatory cytokine cascades (IL-6, IL-12, IL-23, IFN-γ) in UC. JAK inhibitors (tofacitinib targeting JAK1/JAK3; upadacitinib targeting JAK1) are oral small-molecule therapies with demonstrated efficacy. abinScience offers recombinant JAK1 and JAK3 proteins for kinase assays, inhibitor screening, and phospho-specific antibodies for downstream STAT pathway profiling.
→ Browse JAK pathway proteins & antibodies

References

1. Ungaro R, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. DOI

2. Feagan BG, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710. DOI

3. Sandborn WJ, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291. DOI

4. D’Haens G, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. DOI